Biogen Idec
Biogen ventures into ophthalmology with $1-bn AGTC tie-up
04 Jul 2015
The collaboration will focus on the development of a portfolio of therapeutic programmes for orphan diseases of the retina that can lead to blindness in children and adults
Biogen Idec to pay Elan Corp $3.25 bn plus for full rights of multiple sclerosis drug Tysabri
06 Feb 2013
Facet Biotech spurns Biogen’s buyout bid
09 Sep 2009
Biogen Idec up for sale after Icahn offer
By Our Corporate Bureau | 13 Oct 2007
Nicholas Piramal enters into alliance with Biogen Idec, USA
By Mumbai: | 02 Dec 2003
